Date: December 1st 2008
|
| |
I'm really pleased to be able to tell you that we've
assembled a fantastic preliminary line-up at BioTrinity
2009, well in advance of what promises to be the UK's Premier
Biotech and Investment Conference.
A brief look at the preliminary line up of the
first 20+ companies selected for corporate presentations at the upcoming
BioTrinity 2009 conference (April 2-3, Oxford), tells the exciting story
of some of the most successful emerging and growing biotech and medtech
companies in the world - some raising money in
2008. No wonder that registration for 2009 is running
3-fold higher than last year! Vantia Therapeutics, which raised
£19m earlier this year as it spun-out of Ferring Pharma ... more... AdaptImmune, which hit the headlines
with its engineered HIV killer T-cells 2 weeks ago ... more... Circassia, which raised £11m in its
oversubscribed round earlier this year, for immune control technologies
... more... Apitope, which recently raised EUR
10m in a novel series A financing, to develop MS, diabetes and Factor VIII
resistance treatments and diagnostics ... more... Oxford BioMedica which has promising
results with its ProSavin treatment for Parkinsons in phase I/II ... more... Take a look at the Company Showcase
line-up as it begins to develop. If your R&D company wishes to be
considered for selection for one of the few remaining presentation slots,
please make an online application or contact
Jon Rees directly on +44(0)1865594642 Remember: You have just 10 days left to take
advantage of the Early Bird registration offer. New for 2009:
Facts from 2008:
Companies Confirmed for 2009:
Shire Pharma Oxford BioMedica Merck AdaptImmune Eli Lilly Solvias AG Genzyme PharmaTV Bristol Myers-Squibb Intertek (OSI) Prosidion Oxygen Healthcare EUSA Pharma BBSRC Atlas Venture Domainex Takeda Research Investment Inc Hybrid Systems Novo Ventures Innovator Capital MP Healthcare Venture Management Oxford Capital Partners Vantia Therapeutics UniTech Pharma Immunocore Cytox Group Cellzome Eykona Technologies Oxford Gene Technology Plant Vaccines Limited Circassia Alchemy Healthcare GlycoForm Oxford Expression Technologies Glide Pharma Epistem Inhibox Capsant Neurotechnologies Orthox Giles Insurance Apitope Simbec Research Particle Therapeutics Regulatory Resources Group De Facto AbD Serotec Manches Netherlands Foreign Investment Agency MEPC Milton Park UKTI Drug Discovery Today OBN VirdisPharma Interea International EBD Group EAPD Innovations Frank B Dehn TVLSN James Cowper Lab Support UK Ltd PULSE Scientific FOCUS Insurance Fry Heath Spence Oxford Science Park Mewburn Ellis LLP Riverbank IT Teva Pharmaceutical Industries  |
 |
WHO SHOULD ATTEND?Biotech & MedTech Executives
Mid & Large Pharma Executives
Investors
| |
Registration FeesRegister now online at www.biotrinity.com to take advantage of the Early Bird offer which expires December 15th 2008. OBN Member companies can take advantage of the lower rate of £399 + VAT, including a complimentary ticket with the first person registering from within Full Member companies. Do consider registering early to ensure your partnering profile is available when partnering begins on February 17th 2009, before New Year's schedule kicks in. Are you ready to join the 300+ companies expected at BioTrinity 2009? | |
|
Early Bird Registration Fee (until Dec 15, 2008) Special Registration Fee (until Feb 14, 2009) Registration Fee (until April 1, 2009) On-site Registration Fee |
£499 + VAT £549 + VAT £599 + VAT £650 + VAT |
|
| |
|
| Archive Index | |
|
)
BioTrinity test list to marketing email format and style before large scale distribution
Powered by Dada Mail 3.0.0 beta 3 - 05/19/08
Copyright © 1999-2008, Simoni Creative.